GlassScriptPhysician profile
Constantine G Moschonas
NPI 1205965019
$3,226.64
in general payments reported to CMS, 2019-2025
27 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2021: $251 · 2022: $235 · 2023: $512 · 2024: $1,177 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $1,000 · Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $1,000.00 |
| Food and Beverage | $954.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amnio Technology, LLC | $1,119.27 | 2023-2024 | |
| Pinnacle Transplant Technologies, LLC | $763.03 | 2019 | |
| Abbvie INC. | $311.25 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $173.66 | 2021 | |
| Argenx US, INC. | $151.07 | 2022-2024 | Vyvgart Hytrulo |
| Biogen, INC. | $96.43 | 2023 | Vumerity |
| Teva Pharmaceuticals USA, INC. | $90.11 | 2023-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Celgene Corporation | $54.68 | 2021-2025 | Zeposia |
| Eisai INC. | $48.04 | 2024-2025 | |
| Lilly USA, LLC | $47.64 | 2021-2024 | Kisunla |
| Mdd US Operations, LLC | $47.38 | 2025 | |
| Amneal Pharmaceuticals LLC | $42.87 | 2019-2025 | Crexont |
| Acadia Pharmaceuticals INC | $36.62 | 2024-2025 | Nuplazid |
| Pfizer INC. | $34.11 | 2023-2025 | |
| Neurelis, INC. | $26.69 | 2022-2024 | Valtoco |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $24.98 | 2023 | Soliris |
| Ucb, INC. | $24.16 | 2024 | Briviact |
| Aprecia Pharmaceuticals, LLC | $22.42 | 2022 | |
| Corium, LLC | $22.32 | 2023 | Adlarity |
| Neurocrine Biosciences, INC. | $20.56 | 2025 | |
| Sumitomo Pharma America, INC. | $19.54 | 2023 | Aptiom |
| Lundbeck LLC | $17.96 | 2022 | |
| Upsher-Smith Laboratories LLC | $16.88 | 2022 | |
| Genentech USA, INC. | $14.97 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constantine Moschonas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.